Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 11, 2015 - Issue 6
Submit an article Journal homepage
1,899
Views
31
CrossRef citations to date
0
Altmetric
Research Paper

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Alain LuxembourgMerck & Co., Inc.; Whitehouse Station, NJ, USACorrespondence[email protected]
,
Darron BrownDepartment of Medicine; Indiana University School of Medicine; Indianapolis, IN, USA
,
Celine BouchardUniversité Laval; Québec, Canada
,
Anna R GiulianoMoffitt Cancer Center; Tampa, FL, USA
,
Ole-Erik IversenDepartment of Clinical Medicine; University of Bergen/Haukeland University Hospital; Bergen, Norway
,
Elmar A JouraMedical University of Vienna; Comprehensive Cancer Center (CCC); Vienna, Austria
,
Mary E PennyInstituto de Investigación Nutricional; Lima, Peru
,
Jaime A RestrepoCentro de Investigation Clinica; Medellin, Colombia
,
Josefina RomagueraUniversity of Puerto Rico; Medical Sciences Campus; San Juan, Puerto Rico
,
Roger MaanssonMerck & Co., Inc.; Whitehouse Station, NJ, USA
,
Erin MoellerMerck & Co., Inc.; Whitehouse Station, NJ, USA
,
Michael RitterMerck & Co., Inc.; Whitehouse Station, NJ, USA
&
Joshua ChenMerck & Co., Inc.; Whitehouse Station, NJ, USA
 show all
Pages 1313-1322 | Received 01 Oct 2014, Accepted 03 Dec 2014, Published online: 18 Jun 2015

References

  • Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 2007; 11 Suppl 2: S3-S9; PMID:18162244; http://dx.doi.org/10.1016/S1201-9712(07)60015-0
  • Madkan VK, Cook-Norris RH, Steadman MC, Arora A, Mendoza N, Tyring SK. The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol 2007; 157: 228-41; PMID:17553059; http://dx.doi.org/10.1111/j.1365-2133.2007.07961.x
  • Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 2007; 29: 155-62; PMID:17022088; http://dx.doi.org/10.1002/hed.20491
  • Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5: F12-3; PMID:23199955; http://dx.doi.org/10.1016/j.vaccine.2012.07.055
  • Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Suppl 5: F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
  • de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
  • Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7: 38; PMID:23273245; http://dx.doi.org/10.1186/1750-9378-7-38
  • Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012; 30 Suppl 5: F83-7; PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106
  • Brown D, Muller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine 2014; 32: 5880-7; PMID:25148777; http://dx.doi.org/10.1016/j.vaccine.2014.08.004
  • Chen J, Gesser R, Luxembourg A. A seamless Phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clinical Trials 2015; 12 1:84–90.
  • Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711–23.
  • Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014; 10; PMID:25424920; http://dx.doi.org/10.4161/hv.29205
  • Villa LL, Ault K, Giuliano AR, Costa RLR, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24: 5571-83; PMID:16753240; http://dx.doi.org/10.1016/j.vaccine.2006.04.068

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.